All In Biotech

BLA 021017 · Lilly

Humalog Mix 75/25 Pen

Insulin Lispro Protamine Recombinant, Insulin Lispro Recombinant · Injection · Insulin Analog

Last checked: Nov 19, 2026Latest source record: Jul 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Dec 22, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

0 Phase 3, 0 recruiting

FAERS reports

132,953

62,518 serious, 5,883 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 16, 2026.

HUMALOG Mix75/25 is indicated to improve glycemic control in adults with diabetes mellitus. HUMALOG ® Mix75/25™ is a mixture of insulin lispro protamine, an intermediate-acting human insulin analog, and insulin lispro, a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. ( 1 ) Limitations of Use: The proportions of rapid-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. ( 1 ) Limitations of Use : The proportions of rapid-acting and intermediate-acting insulins in HUMALOG Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.

Mechanism: The primary activity of insulin, including HUMALOG Mix75/25, is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 1999 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LetterReviewLabel
3 products under this application
  • HUMALOG MIX 75/25 PEN · INSULIN LISPRO PROTAMINE RECOMBINANT 75 UNITS/ML; INSULIN LISPRO RECOMBINANT 25 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • HUMALOG MIX 75/25 · INSULIN LISPRO PROTAMINE RECOMBINANT 75 UNITS/ML; INSULIN LISPRO RECOMBINANT 25 UNITS/ML · INJECTABLE, INJECTION · Prescription
  • HUMALOG MIX 75/25 KWIKPEN · INSULIN LISPRO PROTAMINE RECOMBINANT 75 UNITS/ML; INSULIN LISPRO RECOMBINANT 25 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Lispro Protamine Recombinant" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased37,220
  • incorrect dose administered8,870
  • blood glucose decreased8,618
  • drug ineffective7,963
  • visual impairment5,346
  • nausea4,883
  • malaise3,961
  • hypoglycaemia3,846
  • fatigue3,774
  • drug dose omission3,675
  • fall3,456
  • underdose3,348

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,188
20051,273
20061,695
20071,565
20081,472
20091,807
20101,862
20112,034
20122,134
20131,766
20144,651
201528,030
20169,278
20178,866
20189,207
20199,220
20209,347
20217,818
20226,740
20235,890
20245,470
20257,844
20263,796

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Sep 1, 2026

    Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05). A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Humalog Mix 75-25 (Insulin Lispro Protamin/Lispro)

2024 spending

$14.3M

Beneficiaries

11,801

55,075 claims

Per beneficiary

$1,213

$8.07 per unit

View as table
YearSpending
2020$89,208,218
2021$79,517,909
2022$68,003,335
2023$59,917,382
2024$14,315,749

Part D: Humalog Mix 75-25 Kwikpen (Insulin Lispro Protamin/Lispro)

2024 spending

$53.0M

Beneficiaries

39,245

157,545 claims

Per beneficiary

$1,351

$9.80 per unit

View as table
YearSpending
2020$277,054,166
2021$250,811,374
2022$226,141,891
2023$213,875,690
2024$53,030,308

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Eli Lilly · Also marketed as Humalog Mix 75/25, Humalog Mix 75/25 Kwikpen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.